Strategic partnerships Grünenthal recently expanded collaboration activity with CNATM and Merz Therapeutics in multiple regions, signaling openness to joint development and distribution opportunities that can be leveraged for co-commercialization, licensing, or strategic alliances in pain management and related therapies.

Global footprint With affiliates in 28 countries and products available in about 100 countries, Grünenthal presents a wide geographic expansion path for partner solutions, regional market access programs, and localization of manufacturing or regulatory support services.

Innovation pipeline Completed Phase I trial for a nociceptin receptor agonist demonstrates a focus on novel non-opioid pain mechanisms, indicating opportunities to align with biotech and CROs for early-phase collaboration, biomarker development, and tech-enabled trial solutions.

Financial scale Reported revenues approaching €1.8 billion in 2025 and a broader revenue profile above $10B in referenced comparisons, suggesting Grünenthal as a sizeable partner with potential for larger-scale deals, co-funding of therapies, and global commercialization capabilities.

Supply and access Existing partnerships to broaden Canadian patient access and global rights acquisitions point to opportunities in market access, payer engagement, and distribution enhancements, including technology-enabled pricing, data analytics, and patient support programs.